{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:11:43Z","timestamp":1788855103944,"version":"build-2803163510"},"reference-count":158,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Sarcoidosis is a multiorgan immunological disease characterized by an exaggerated inflammatory response leading to non-caseating granuloma formation. Cutaneous sarcoidosis lesions serve as an accessible site for biopsy that can assist with earlier identification and treatment of sarcoid disease. This review synthesizes recent advances in the understanding of cutaneous sarcoidosis immunopathogenesis, with a focus on lymphocyte signaling, and describes the therapeutic implications of this immune dysregulation. While it is known that Th1 and Th17 cell subsets contribute to general non-caseating granuloma formation, recent studies identify Th17.1 cells as the predominant producers of IFN-\u03b3, challenging classical paradigms. Th2 polarization and elevated thymus and activation-regulated chemokine (TARC) levels, along with regulatory T cell dysfunction and PD-1 overexpression, contribute to chronic inflammation and fibrosis in the cutaneous sarcoidosis disease state. The JAK\/STAT pathway is notably upregulated in cutaneous sarcoid granulomas, and JAK inhibitors have demonstrated promising efficacy as an avenue for treatment. Additional immune mechanisms at play in cutaneous sarcoidosis include mTOR and TLR dysregulation as well as B-cell dysfunction. Infectious triggers and DNA polymorphisms associated with genetic susceptibility further support the multifactorial nature of cutaneous sarcoidosis. Based on current literature and clinical guidelines, we propose treatment options for cutaneous sarcoidosis which target dysregulated aspects of the immune response. While prednisone and corticotropin gel remain the only FDA-approved therapies for cutaneous sarcoidosis, improved understanding of sarcoidosis signaling may lead to promising new therapeutic approaches. With the growing understanding of lymphocyte signaling defects in cutaneous sarcoidosis, physicians will be better equipped to identify and treat the underlying mechanisms of this disease.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1711377","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:02:16Z","timestamp":1788854536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Lymphocyte signal transduction defects in cutaneous sarcoidosis and implications for treatment"],"prefix":"10.3389","volume":"17","author":[{"given":"Julia","family":"Lunt","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville","place":["Greenville, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Shidhaye","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville","place":["Greenville, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fasana","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville","place":["Greenville, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville","place":["Greenville, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville","place":["Greenville, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville","place":["Greenville, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville","place":["Greenville, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"McCain","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of South Carolina","place":["Columbia, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Schammel","sequence":"additional","affiliation":[{"name":"Department of Pathology, Prisma Health","place":["Greenville, SC, United States"]},{"name":"Pathology Associates and Consultants","place":["Greenville, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Fiester","sequence":"additional","affiliation":[{"name":"Pathology Associates and Consultants","place":["Greenville, SC, United States"]},{"name":"Department of Biological Sciences, Florida Gulf Coast University","place":["Fort Myers, FL, United States"]},{"name":"Department of Chemistry, Furman University","place":["Greenville, SC, United States"]},{"name":"School of Health Research, Clemson University","place":["Clemson, SC, United States"]},{"name":"Family Medicine Residency at Lee Health, Florida State University College of Medicine","place":["Fort Myers, FL, United States"]},{"name":"Internal Medicine Residency at Lee Health, Florida State University College of Medicine","place":["Cape Coral, FL, United States"]},{"name":"Academic Medicine Enterprise, Lee Health","place":["Fort Myers, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Arce","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville","place":["Greenville, SC, United States"]},{"name":"Prisma Health Cancer Institute, Prisma Health System","place":["Greenville, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer T.","family":"Grier","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville","place":["Greenville, SC, United States"]},{"name":"Department of Pathology, Prisma Health","place":["Greenville, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4103\/jomfp.jomfp_373_21","article-title":"Sarcoidosis - a review article","volume":"26","author":"Sreeja","year":"2022","journal-title":"J Oral Maxillofac Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2024.12.017","article-title":"Cutaneous sarcoidosis: clinical and pathologic features, molecular pathogenesis, and treatment","volume":"43","author":"Damsky","year":"2025","journal-title":"Clin Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2011.04128.x","article-title":"Specific cutaneous lesions in patients with systemic sarcoidosis: relationship to severity and chronicity of disease","volume":"36","author":"Marcoval","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0738-081x(86)90032-5","article-title":"Cutaneous sarcoidosis: definitions and types of lesions","volume":"4","author":"Elgart","year":"1986","journal-title":"Clin Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28053","article-title":"Sarcoidosis and its dermatological manifestations: a narrative review","volume":"14","author":"Koneti","year":"2022","journal-title":"Cureus"},{"key":"B6","article-title":"Lupus pernio Statpearls","author":"Redissi","year":"2025"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103288","article-title":"A framework for exclusion of alternative diagnoses in sarcoidosis","volume":"149","author":"Harper","year":"2024","journal-title":"J Autoimmun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.680989","article-title":"Granulomatous sarcoidosis mimics","volume":"8","author":"Judson","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220164","article-title":"Pediatric sarcoidosis: retrospective analysis of biopsy-proven patients","volume":"50","author":"Nott","year":"2023","journal-title":"J Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-5231(05)70415-9","article-title":"Immunology of sarcoidosis","volume":"18","author":"Kataria","year":"1997","journal-title":"Clin Chest Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.490","article-title":"Papular sarcoidosis of the knees: a clue for the diagnosis of erythema nodosum-associated sarcoidosis","volume":"49","author":"Marcoval","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"B12","first-page":"59","article-title":"Papular sarcoidosis of the knees. A frequent form of presentation of systemic sarcoidosis","volume":"33","author":"Marcoval","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v106.adv-2026-0482","article-title":"Organ involvement and treatment response across cutaneous sarcoidosis subtypes","volume":"106","author":"Schett","year":"2026","journal-title":"Acta Derm Venereol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2023.4584","article-title":"Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients","volume":"33","author":"Cohen","year":"2023","journal-title":"Eur J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890430098013","article-title":"Cutaneous involvement in sarcoidosis. Relationship to systemic disease","volume":"133","author":"Ma\u00f1\u00e1","year":"1997","journal-title":"Arch Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/01.RHU.0000062509.01658.d1","article-title":"Lupus pernio in sarcoidosis: clinical features and treatment outcomes of 14 patients","volume":"9","author":"Yanardag","year":"2003","journal-title":"J Clin Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.7.869","article-title":"Development of sarcoidosis in cosmetic tattoos","volume":"141","author":"Antonovich","year":"2005","journal-title":"Arch Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/24725625.2020.1816645","article-title":"Tattoo skin reaction as a skin manifestation of systemic sarcoidosis","volume":"5","author":"Mukai","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2007.00040","article-title":"Sarcoidosis appearing in a tattoo","volume":"12","author":"Ali","year":"2008","journal-title":"J Cutan Med Surg"},{"key":"B20","article-title":"Granulomatous cutaneous sarcoidosis: diagnosis, relationship to systemic disease, prognosis and treatment","volume":"30","author":"Ma\u00f1\u00e1","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.137.4.485","article-title":"The presence of foreign bodies does not exclude the diagnosis of sarcoidosis","volume":"137","author":"Callen","year":"2001","journal-title":"Arch Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200607060-00006","article-title":"Cutaneous sarcoidosis: the \"great imitator\": etiopathogenesis, morphology, differential diagnosis, and clinical management","volume":"7","author":"Tchernev","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cells11010059","article-title":"Clinical features, histopathology and differential diagnosis of sarcoidosis","volume":"11","author":"Tana","year":"2021","journal-title":"Cells"},{"key":"B24","article-title":"Comparison of cutaneous sarcoidosis with systemic sarcoidosis: a retrospective analysis","volume":"7","author":"Tong","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.02.003","article-title":"Clinical features of extrapulmonary sarcoidosis without lung involvement","volume":"154","author":"James","year":"2018","journal-title":"Chest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103247","article-title":"The immunopathogenesis of sarcoidosis","volume":"149","author":"Miedema","year":"2024","journal-title":"J Autoimmun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00437","article-title":"Granuloma formation in pulmonary sarcoidosis","volume":"4","author":"Broos","year":"2013","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nri2448","article-title":"Exploring the full spectrum of macrophage activation","volume":"8","author":"Mosser","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2010.11.065","article-title":"M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis","volume":"178","author":"Prokop","year":"2011","journal-title":"Am J Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1159\/000364945","article-title":"M1 and M2 macrophages: the chicken and the egg of immunity","volume":"6","author":"Mills","year":"2014","journal-title":"J Innate Immun"},{"key":"B31","article-title":"Prednisone Statpearls","author":"Puckett","year":"2025"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201507-1499OC","article-title":"Ifn-\u03b3-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells","volume":"193","author":"Ramstein","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/rheumatology\/ker316","article-title":"Increased Il-17a expression in granulomas and in circulating memory T cells in sarcoidosis","volume":"51","author":"Ten Berge","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad438","article-title":"High expression of interleukin-17a in cutaneous sarcoidosis","volume":"190","author":"Shimon","year":"2024","journal-title":"Br J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612792","article-title":"Simultaneous assessment of mtorc1, jak\/stat, and nlrp3 inflammasome activation pathways in patients with sarcoidosis","volume":"24","author":"Kraaijvanger","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.017","article-title":"Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway","volume":"66","author":"Judson","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2014.04.006","article-title":"Gene expression profiles in granuloma tissue reveal novel diagnostic markers in sarcoidosis","volume":"96","author":"Christophi","year":"2014","journal-title":"Exp Mol Pathol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197398","article-title":"Key players and biomarkers of the adaptive immune system in the pathogenesis of sarcoidosis","volume":"21","author":"Zhou","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","volume":"82","author":"Damsky","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.08.012","article-title":"Treatment of cutaneous sarcoidosis with tofacitinib: a case report and review of evidence for Janus kinase inhibition in sarcoidosis","volume":"16","author":"Talty","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdcr.2020.12.021","article-title":"Treatment of cutaneous sarcoidosis with tofacitinib 2% ointment and extra virgin olive oil","volume":"9","author":"Alam","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15426","article-title":"Successful treatment of recalcitrant generalized granuloma annulare with the Jak inhibitor abrocitinib","volume":"22","author":"Michels","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2313090","article-title":"Oral abrocitinib in the treatment of granuloma annulare: a case report","volume":"35","author":"Liu","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S440138","article-title":"Successful treatment of granulomatous rosacea by Jak inhibitor abrocitinib: a case report","volume":"16","author":"Ren","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00127-19","article-title":"Eosinophils and macrophages within the Th2-induced granuloma: balancing killing and healing in a tight space","volume":"87","author":"Ariyaratne","year":"2019","journal-title":"Infect Immun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2022.100153","article-title":"Systemic immune response to vimentin and granuloma formation in a model of pulmonary sarcoidosis","volume":"5","author":"Bagavant","year":"2022","journal-title":"J Transl Autoimmun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.23.15036","article-title":"The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4","volume":"272","author":"Imai","year":"1997","journal-title":"J Biol Chem"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2018.02.011","article-title":"TARC expression in the circulation and cutaneous granulomas correlates with disease severity and indicates Th2-mediated progression in patients with sarcoidosis","volume":"67","author":"Nguyen","year":"2018","journal-title":"Allergol Int"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2016.1158311","article-title":"Targeting Cd1c-expressing classical dendritic cells to prevent thymus and activation-regulated chemokine (Tarc)-mediated T-cell chemotaxis in rheumatoid arthritis","volume":"46","author":"Hillen","year":"2017","journal-title":"Scand J Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.1.122","article-title":"Human Th17 cells share major trafficking receptors with both polarized effector T cells and Foxp3+ regulatory T cells","volume":"180","author":"Lim","year":"2008","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.812774","article-title":"Toll-like receptor signaling and its role in cell-mediated immunity","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12094","article-title":"Expression of Cd39\/Entpd1 on granuloma-composing cells and induction of Foxp3-positive regulatory T cells in sarcoidosis","volume":"38","author":"Fujimura","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/00000372-198410000-00002","article-title":"Demonstration in situ of subsets of T-lymphocytes in sarcoidosis","volume":"6","author":"Modlin","year":"1984","journal-title":"Am J Dermatopathol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13081378","article-title":"Circulating regulatory T cell subsets in patients with sarcoidosis","volume":"13","author":"Kudryavtsev","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050648","article-title":"The immune paradox of sarcoidosis and regulatory T cells","volume":"203","author":"Miyara","year":"2006","journal-title":"J Exp Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1301991","article-title":"Foxp3+ regulatory T cells are associated with the severity and prognosis of sarcoidosis","volume":"14","author":"Patterson","year":"2023","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1185443","article-title":"Imbalanced distribution of regulatory T cells and Th17.1 cells in the peripheral blood and Balf of sarcoidosis patients: Relationship to disease activity and the fibrotic radiographic phenotype","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2353\/ajpath.2009.080580","article-title":"Foxp3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions","volume":"174","author":"Taflin","year":"2009","journal-title":"Am J Pathol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.clim.2011.03.015","article-title":"Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation","volume":"140","author":"Rappl","year":"2011","journal-title":"Clin Immunol"},{"key":"B62","article-title":"Effects of Foxp3 gene polymorphism in sarcoidosis patients","volume":"24","author":"Takano","year":"2007","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roae106","article-title":"The abundance of regulatory T cell subsets is associated with the clinical outcomes of sarcoidosis","volume":"35","author":"Kusaka","year":"2025","journal-title":"Mod Rheumatol"},{"key":"B64","article-title":"Pd-1\/Pd-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1165\/rcmb.2016-0037OC","article-title":"Programmed death-1 inhibition of phosphatidylinositol 3-kinase\/Akt\/mechanistic target of rapamycin signaling impairs sarcoidosis Cd4+ T cell proliferation","volume":"56","author":"Celada","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar8356","article-title":"Pd-1 up-regulation on Cd4+ T cells promotes pulmonary fibrosis through Stat3-mediated Il-17a and Tgf-B1 production","volume":"10","author":"Celada","year":"2018","journal-title":"Sci Transl Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2016.06.004","article-title":"Pembrolizumab-associated sarcoidosis","volume":"2","author":"Cotliar","year":"2016","journal-title":"JAAD Case Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.02.015","article-title":"Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma","volume":"3","author":"Birnbaum","year":"2017","journal-title":"JAAD Case Rep"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002031","article-title":"The link between the Pdl1 costimulatory pathway and Th17 in fetomaternal tolerance","volume":"187","author":"D'Addio","year":"2011","journal-title":"J Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201401-0188OC","article-title":"Blockade of the programmed death-1 pathway restores sarcoidosis Cd4(+) T-cell proliferative capacity","volume":"190","author":"Braun","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.36141\/svdld.v40i2.13498","article-title":"Cellular recycling gone wrong: The role of dysregulated autophagy and hyperactive Mtorc1 in the pathogenesis of sarcoidosis","volume":"40","author":"Adouli","year":"2023","journal-title":"Sarcoidosis Vasculitis Diffuse Lung Dis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M900573200","article-title":"Ulk1.Atg13.Fip200 complex mediates Mtor signaling and is essential for autophagy","volume":"284","author":"Ganley","year":"2009","journal-title":"J Biol Chem"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e08-12-1248","article-title":"Nutrient-dependent Mtorc1 association with the Ulk1-Atg13-Fip200 complex required for autophagy","volume":"20","author":"Hosokawa","year":"2009","journal-title":"Mol Biol Cell"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1091\/mbc.e08-12-1249","article-title":"Ulk-Atg13-Fip200 complexes mediate Mtor signaling to the autophagy machinery","volume":"20","author":"Jung","year":"2009","journal-title":"Mol Biol Cell"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.4161\/auto.7.8.15860","article-title":"Ampk and Mtor coordinate the regulation of Ulk1 and mammalian autophagy initiation","volume":"7","author":"Shang","year":"2011","journal-title":"Autophagy"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.4161\/auto.19653","article-title":"Mtorc1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of Tfeb","volume":"8","author":"Martina","year":"2012","journal-title":"Autophagy"},{"key":"B78","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/imr.12845","article-title":"Mtor signaling at the crossroads of environmental signals and T-cell fate decisions","volume":"295","author":"Huang","year":"2020","journal-title":"Immunol Rev"},{"key":"B79","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ni.2005","article-title":"The kinase Mtor regulates the differentiation of helper T cells through the selective activation of signaling by Mtorc1 and Mtorc2","volume":"12","author":"Delgoffe","year":"2011","journal-title":"Nat Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/ni.3655","article-title":"Chronic signaling via the metabolic checkpoint kinase Mtorc1 induces macrophage granuloma formation and marks sarcoidosis progression","volume":"18","author":"Linke","year":"2017","journal-title":"Nat Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12931-018-0748-5","article-title":"G908r Nod2 variant in a family with sarcoidosis","volume":"19","author":"Besnard","year":"2018","journal-title":"Respir Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000816","article-title":"The signaling axis of Rac1-Tfeb regulates autophagy and tumorigenesis","volume":"30","author":"Ma","year":"2019","journal-title":"Anticancer Drugs"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1080\/21541248.2016.1224399","article-title":"Rac1 and Rhoa: Networks, loops and bistability","volume":"9","author":"Nguyen","year":"2018","journal-title":"Small GTPases"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.01.007","article-title":"Sarcoidosis and the Mtor, Rac1, and autophagy triad","volume":"41","author":"Pacheco","year":"2020","journal-title":"Trends Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00302-8","article-title":"Efficacy and safety of Mtor inhibition in cutaneous sarcoidosis: A single-centre trial","volume":"6","author":"Redl","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3519","article-title":"Responsiveness to change and establishment of the minimal clinically important difference for the cutaneous sarcoidosis activity and morphology instrument","volume":"156","author":"Noe","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.60","article-title":"Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis","volume":"149","author":"Rosenbach","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1600-065X.2008.00628.x","article-title":"Th17 cells in human disease","volume":"223","author":"Tesmer","year":"2008","journal-title":"Immunol Rev"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.880359","article-title":"The interaction between autophagy and Jak\/Stat3 signaling pathway in tumors","volume":"13","author":"Xu","year":"2022","journal-title":"Front Genet"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00046-08","article-title":"Pathogen recognition and inflammatory signaling in innate immune defenses","volume":"22","author":"Mogensen","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"B91","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/DAD.0000000000000199","article-title":"Identifying toll-like receptor expression in cutaneous sarcoidosis","volume":"37","author":"Huizenga","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2015.91","article-title":"Toll-like receptors: Potential targets for lupus treatment","volume":"36","author":"Wu","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043588","article-title":"Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased Il-10-producing regulatory B cells and high Baff levels","volume":"7","author":"Saussine","year":"2012","journal-title":"PloS One"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket186","article-title":"Elevated serum Baff levels in patients with sarcoidosis: Association with disease activity","volume":"52","author":"Ueda-Hayakawa","year":"2013","journal-title":"Rheumatol (Oxford)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05118-11","article-title":"Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis","volume":"18","author":"Lee","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4183-2","article-title":"Significant elevation of the levels of B-cell activating factor (Baff) in patients with sarcoidosis","volume":"37","author":"Ando","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.01.025","article-title":"Rituximab as a treatment alternative in sarcoidosis","volume":"75","author":"Belkhou","year":"2008","journal-title":"Joint Bone Spine"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","author":"Sweiss","year":"2014","journal-title":"Eur Respir J"},{"key":"B99","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00415-025-13209-7","article-title":"Rituximab in pathologically confirmed sarcoidosis affecting the central nervous system: A multi-center retrospective study","volume":"272","author":"Hutto","year":"2025","journal-title":"J Neurol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00428-8","article-title":"Biologic therapy in the treatment of cutaneous sarcoidosis: A literature review","volume":"20","author":"Dai","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12793","article-title":"Sarcoidosis following successful treatment of pemphigus vulgaris with rituximab: A rituximab-induced reaction further supporting B-cell contribution to sarcoidosis pathogenesis","volume":"41","author":"Galimberti","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2017.3143","article-title":"Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: An uncommon adverse effect","volume":"27","author":"Pescitelli","year":"2017","journal-title":"Eur J Dermatol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13693","article-title":"Scar sarcoidosis following rituximab therapy","volume":"33","author":"Vesely","year":"2020","journal-title":"Dermatol Ther"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.12890\/2024_005070","article-title":"From fibrosis to granuloma: Drug induced systemic sarcoidosis-like reaction after rituximab in a patient with primary Sj\u00f6gren's syndrome","volume":"11","author":"Coelho","year":"2024","journal-title":"Eur J Case Rep Intern Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.594133","article-title":"Emerging molecular targets for the treatment of refractory sarcoidosis","volume":"7","author":"Boleto","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25887","article-title":"The role of belimumab in systemic lupus erythematosis: A systematic review","volume":"14","author":"Joy","year":"2022","journal-title":"Cureus"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.1999.tb01844.x","article-title":"Identification of mycobacterial DNA in cutaneous lesions of sarcoidosis","volume":"26","author":"Li","year":"1999","journal-title":"J Cutan Pathol"},{"key":"B108","article-title":"Detection and identification of mycobacterial gene in skin lesions and lymph nodes in patients with sarcoidosis","volume":"31","author":"Ding","year":"2009","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15042","article-title":"Identification of Mycobacterium tuberculosis and non-tuberculous mycobacteria from cutaneous sarcoidosis lesions by reverse blot hybridization assay","volume":"46","author":"Lee","year":"2019","journal-title":"J Dermatol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.4646","article-title":"Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: A randomized, single-masked, placebo-controlled study","volume":"149","author":"Drake","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.2977","article-title":"Oral minocycline in treatment of cutaneous sarcoidosis","volume":"149","author":"Steen","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.5070\/d3208023529","article-title":"Rapid response of tattoo-associated cutaneous sarcoidosis to minocycline: Case report and review of the literature","volume":"20","author":"Sheu","year":"2014","journal-title":"Dermatol Online J"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1038\/s41467-025-57829-z","article-title":"Gwas identifies genetic loci, lifestyle factors and circulating biomarkers that are risk factors for sarcoidosis","volume":"16","author":"Yuan","year":"2025","journal-title":"Nat Commun"},{"key":"B114","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s42003-020-01185-9","article-title":"Genetic control of Ccl24, Por, and Il23r contributes to the pathogenesis of sarcoidosis","volume":"3","author":"Meguro","year":"2020","journal-title":"Commun Biol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq325","article-title":"Sarcoidosis Hla class II genotyping distinguishes differences of clinical phenotype across ethnic groups","volume":"19","author":"Sato","year":"2010","journal-title":"Hum Mol Genet"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.10.040","article-title":"Sarcoidosis treatment patterns in the United States: 2016-2022","volume":"167","author":"Sangani","year":"2025","journal-title":"Chest"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"Ers clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"B118","article-title":"Ats\/Ers\/Wasog statement on sarcoidosis. American Thoracic Society\/European Respiratory Society\/World Association of Sarcoidosis and Other Granulomatous Disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.05.040","article-title":"Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: Single-center retrospective study of 9 patients","volume":"66","author":"Sen\u00e9","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B120","article-title":"Infliximab for chronic cutaneous sarcoidosis: A subset analysis from a double-blind randomized clinical trial","volume":"32","author":"Baughman","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.056","article-title":"A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis","volume":"68","author":"Pariser","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.1162","article-title":"Efficacy and tolerance of anti-tumor necrosis factor A agents in cutaneous sarcoidosis: A French study of 46 cases","volume":"153","author":"Heidelberger","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.84970","article-title":"Tumor necrosis factor-alpha inhibitor-induced sarcoid-like reaction in a patient with juvenile idiopathic arthritis: A case report","volume":"17","author":"Aung","year":"2025","journal-title":"Cureus"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.03.056","article-title":"Drug-induced sarcoidosis-like reactions","volume":"154","author":"Chopra","year":"2018","journal-title":"Chest"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.991783","article-title":"Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches","volume":"9","author":"Obi","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B126","article-title":"Methotrexate Statpearls","author":"Hanoodi","year":"2025"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430080088011","article-title":"Prolonged use of methotrexate for sarcoidosis","volume":"155","author":"Lower","year":"1995","journal-title":"Arch Intern Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70071-9","article-title":"Weekly low-dose methotrexate therapy for cutaneous sarcoidosis","volume":"24","author":"Webster","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1977.tb15068.x","article-title":"Cutaneous sarcoidosis treated with methotrexate","volume":"97","author":"Veien","year":"1977","journal-title":"Br J Dermatol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1177\/12034754221101361","article-title":"Methotrexate for cutaneous sarcoidosis: A dermatology-based case series of 23 patients","volume":"26","author":"Hrin","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012476","article-title":"Hydroxychloroquine in rheumatic autoimmune disorders and beyond","volume":"12","author":"Nirk","year":"2020","journal-title":"EMBO Mol Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2020.1839959","article-title":"Hydroxychloroquine: A comprehensive review and its controversial role in coronavirus disease 2019","volume":"53","author":"Bansal","year":"2021","journal-title":"Ann Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1177\/0961203396005001081","article-title":"Treatment of primary Sj\u00f6gren's syndrome with hydroxychloroquine: A retrospective, open-label study","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2013(06)07","article-title":"Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients","volume":"68","author":"Silva","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170737","article-title":"Hydroxychloroquine inhibits the differentiation of Th17 cells in systemic lupus erythematosus","volume":"45","author":"Yang","year":"2018","journal-title":"J Rheumatol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: From malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70246-e","article-title":"Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas","volume":"23","author":"Jones","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_1152_2022","article-title":"Jak-Stat inhibitors in immune mediated diseases: An overview","volume":"89","author":"Shah","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000001196","article-title":"New therapeutic options in sarcoidosis","volume":"31","author":"Nunes","year":"2025","journal-title":"Curr Opin Pulm Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.39970","article-title":"Successful therapy of severe and refractory cutaneous sarcoidosis with baricitinib","volume":"104","author":"Russo","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/FJC.0000000000001470","article-title":"Cardiovascular risk management in patients treated with Janus kinase inhibitors","volume":"83","author":"Shah","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with Jak inhibitors in 126,815 reports from the Who pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2630-y","article-title":"Everolimus: Side effect profile and management of toxicities in breast cancer","volume":"140","author":"Paplomata","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt233","article-title":"Acute tubular necrosis associated with Mtor inhibitor therapy: A real entity biopsy-proven","volume":"24","author":"Izzedine","year":"2013","journal-title":"Ann Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.11.027","article-title":"Chest Ct diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: A position paper from the Fleischner Society","volume":"159","author":"Johkoh","year":"2021","journal-title":"Chest"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29887","article-title":"Mtor inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm","volume":"138","author":"Willemsen","year":"2016","journal-title":"Int J Cancer"},{"key":"B147","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14712598.2018.1427727","article-title":"Potential immunotherapies for sarcoidosis","volume":"18","author":"Le","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"B148","article-title":"Rituxan [Package Insert","author":"Genentech","year":"1997"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2015.2666","article-title":"Prognostic value of skin lesions in sarcoidosis: Clinical and histopathological clues","volume":"25","author":"Esteves","year":"2015","journal-title":"Eur J Dermatol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3109\/09546630903440098","article-title":"Clinical and histopathological analysis of specific lesions of cutaneous sarcoidosis in Korean patients","volume":"22","author":"Jung","year":"2011","journal-title":"J Dermatolog Treat"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1347","article-title":"The treatment of lupus pernio: Results of 116 treatment courses in 54 patients","volume":"135","author":"Stagaki","year":"2009","journal-title":"Chest"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.qjmed.a067778","article-title":"Prognostic factors predicting the outcome of sarcoidosis: An analysis of 818 patients","volume":"52","author":"Neville","year":"1983","journal-title":"Q J Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.25251\/btwtbw27","article-title":"Dupilumab treatment for pruritus-associated cutaneous sarcoidosis","volume":"31","author":"Choi","year":"2025","journal-title":"Dermatol Online J"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.36141\/svdld.v41i3.15445","article-title":"Hydroxychloroquine monotherapy in sarcoidosis: Indications, efficacy, and side effects","volume":"41","author":"Vermeer","year":"2024","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"B155","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12948-015-0025-9","article-title":"Rituximab in refractory sarcoidosis: A single centre experience","volume":"13","author":"Cinetto","year":"2015","journal-title":"Clin Mol Allergy"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ec7ff9","article-title":"A case of neurosarcoidosis successfully treated with rituximab","volume":"75","author":"Bomprezzi","year":"2010","journal-title":"Neurology"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S35521","article-title":"Rituximab for refractory granulomatous eye disease","volume":"6","author":"Lower","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfop.2024.100120","article-title":"From eyelid discomfort to sarcoidosis diagnosis: A patient's journey","volume":"7","author":"Tlemcani","year":"2024","journal-title":"JFO Open Ophthalmol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1711377\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:02:20Z","timestamp":1788854540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1711377\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":158,"alternative-id":["10.3389\/fimmu.2026.1711377"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1711377","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1711377"}}